Aller au contenu

Lee-Hwa Tai

Professeure, Faculté de médecine et des sciences de la santé

FMSS Dép. d'immunologie et de biologie cellulaire

Présentation

Sujet de recherche

Cell Therapy of Cancer, Host-Tumour Interaction, Immunotherapy, Vaccine and Cancer, Virus

Disciplines de recherche

Immunology, Microbiology, Virology

Mots-clés

cancer immunology, cancer vaccines, immunotherapy, oncolytic viruses

Intérêts de recherche

Our research program is focused on understanding how reciprocal communication between cancer cells and diverse immune and stromal cell types in the tumor microenvironment controls tumor metastasis and modulates the response to therapeutic intervention. We employ a range of complementary strategies to interrogate the tumor microenvironment including the comprehensive analysis of patient samples (proteomics, immune phenotyping, RNAseq, etc), 3D organoid co-culture systems to mimic the tumor microenvironment, mouse models of cancer, and multi-modal in vivo imaging platforms. We currently have multiple projects focused on exploring the tumor microenvironment of primary and metastatic breast, bladder and pancreatic cancers. Our ultimate goal is to apply this knowledge to the clinic and develop targeted therapies that disrupt essential tumor-microenvironment interactions for the benefit of patients.

Centre de recherche

None

Langues parlées et écrites

Anglais, Français

Diplômes

(2015). (Post-doctorate, Postdoctoral Fellowship). Ottawa Hospital Research Institute.

(2010). (Doctorate, Ph.D. Thesis based). McGill University.

(2005). (Diploma, Advanced Diploma in Applied Health Science). Michener Institute for Applied Health Sciences.

(2003). (Bachelor's, Honours Bachelor's of Science). University of Toronto.

Expérience académique

Director of the Cancer Research Axis, CRCHUS. (2021-). Centre Hospitalier Univ. de Sherbrooke. Canada.

Associate Professor. (2020-). Université de Sherbrooke. Canada.

Assistant Professor. (2016-2020). Université de Sherbrooke. Canada.

Research Associate. (2015-2016). Ottawa Hospital Research Institute. Canada.

Post-doctoral Fellow. (2010-2015). Ottawa Hospital Research Institute. Canada.

Lecturer - Innate Immunology. (2012-2012). University of Ottawa. Canada.

Ph.D. Candidate. (2005-2010). McGill University. Canada.

Lecturer - Introductory Microbiology. (2009-2009). McGill University. Canada.

Teaching Assistant - Introductory Microbiology. (2009-2009). McGill University. Canada.

Teaching Assistant - Advanced Immunology. (2008-2008). McGill University. Canada.

Teaching Assistant - Introductory Microbiology. (2007-2007). McGill University. Canada.

Teaching Assistant - Biochemistry. (2007-2007). McGill University. Canada.

Teaching Assistant - Introductory Microbiology. (2006-2006). McGill University. Canada.

Medical Lab Technologist. (2004-2005). Michener Institute for Applied Health Sciences. Canada.

Medical Lab Technologist. (2004-2004). Michener Institute for Applied Health Sciences. Canada.

Prix et distinctions

  • (2024) CRMUS - Chair in Translational Immunotherapy Research. Université de Sherbrooke. (Prize / Award).
  • (2021) CIHR New Investigator Award. Canadian Institutes of Health Research. (Prize / Award).
  • (2020) FRQS Chercheurs Boursiers, Junior 1. Fonds de recherche du Québec - Santé (FRQS). (Prize / Award).
  • (2018) CRS Scholarship for the Next Generation of Scientists. Cancer Research Society. (Prize / Award).
  • (2015) CIHR Postdoctoral Fellowship. Canadian Institutes of Health Research. (Prize / Award).
  • (2013) FRQS Postdoctoral Fellowship. Fonds de recherche du Québec - Santé (FRQS). (Prize / Award).
  • (2009) CIHR-IRCM Doctoral Research Award. Institut de recherche clinique de Montreal and Canadian Institutes of Health joint program. (Prize / Award).
  • (2007) Invitrogen Canada Master's Research Award. Institut de recherche clinique de Montreal and Invitrogen Canada. (Prize / Award).
  • CIHR Banting and Best Doctoral Research Award. Canadian Institutes of Health Research. (Prize / Award).
  • Career Award in Cancer for top ranked grant for CIHR Project Scheme competition - ICR/CIHR. Canadian Institutes of Health Research. (Prize / Award).
  • Dr. Michael McBurney Postdoctoral Award, for best research productivitiy. University of Ottawa. (Prize / Award).
  • Early Career Researcher Award to attend Canadian Cancer Research Conference. Canadian Institutes of Health Research. (Prize / Award).
  • FRQS Junior 2 Researcher-Scholar Award. Fonds de recherche du Québec - Santé (FRQS). (Prize / Award).
  • Irving Family Foundation Cancer Immunology Symposium Award - Early Researcher Award. Irving Family Foundation. (Prize / Award).
  • Junior Investigator Travel Award. Canadian Cancer Society Research Institute. (Prize / Award).
  • Oral Presentation Award. University of Ottawa. (Prize / Award).
  • Oral Presentation Award. Ottawa Hospital Research Institute. (Prize / Award).
  • Oral presentation. Ottawa Hospital Research Institute. (Prize / Award).
  • Travel Award. Canadian Cancer Society Research Institute. (Prize / Award).
  • Travel Award (Biotherapeutics for Cancer Treatment). Networks of Centres of Excellence. (Prize / Award).

Financement

  • Grant. (Awarded). Principal Applicant. Improving autologous cancer cell vaccines for triple negative breast cancer. Canadian Cancer Society. Emerging Scholars Award. 500 000 $. (2021-2026)
  • Grant. (Awarded). Co-investigator. Pioneering pre- and post-operative integrative care to improve thoracic cancer quality of care, the thoracic peri-operative integrative surgical care evaluation (POISE) trial.. Lotte & John Hecht Memorial Foundation. Clinical Research Grant. 3 853 888 $. (2014-2025)
  • Research Chair. (Awarded). Principal Investigator. Universite de Sherbrooke - Chair in Translational Immunotherapy Research. C.R.M.U.S. (Univ. Sherbrooke). Centre de Recherche Medicale de l'Universite de Sherbrooke Research Chair. 240 000 $. (2019-2024)
  • Grant. (Awarded). Principal Investigator. Targeting metastatic disease of triple negative breast cancer with an immunogenic cancer vaccine. Canadian Institutes of Health Research (CIHR). Project Grant. 703 800 $. (2019-2024)
  • Grant. (Awarded). Principal Applicant. Validation of a Synthetic Live Biotherapeutic for the Delivery of Checkpoint Inhibitors and Tumor Antigens for the Treatment of Solid Tumors. Genome Quebec. Genomic Integration Program. 135 000 $. (2021-2023)
  • (Awarded). Principal Investigator. VSVd51-LIGHT oncolytic virotherapy for pancreatic cancer. Cancer Research Institute of the University of Sherbrooke. Pilot Project Grant. 15 000 $. (2022-2023)
  • Grant. (Awarded). Principal Investigator. Cellular energetics in natural killer cell development and function. Natural Sciences and Engineering Research Council of Canada (NSERC). Discovery Grant. 130 000 $. (2017-2022)
  • Grant. (Awarded). Co-investigator. Pôle d’excellence en Neurosciences : Neuropôle. CRCHUS. Pole d'Excellence en Recherche au CRCHUS. 70 000 $. (2019-2021)
  • Grant. (Awarded). Principal Applicant. CIHR New Investigator Award. Canadian Institutes of Health Research (CIHR). New Investigator Award. 300 000 $. (2016-2021)
  • Grant. (Completed). Co-investigator. Developing gastrointestinal tumor organoid microenvironment models for testing oncolytic viruses.. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Projet Structurant. 75 000 $. (2019-2021)
  • Grant. (Completed). Principal Investigator. Developing immune reconstituted glioblastoma tumor neurospheres to evaluate treatment efficacy with cannabinoids and immunotherapy.. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Projet Structurant. 75 000 $. (2020-2021)
  • Grant. (Completed). Co-investigator. The Sherbrooke Personalized Cancer Avatar Model Initiative: A Feasibility Study of Treatment Guided by the Combination of DNA Profiling and Next-Generation Medical Avatars in Patients with Advanced Kidney Cancer.. MEDTEQ Consortium. Medteq. 703 760 $. (2018-2021)
  • Grant. (Completed). Co-investigator. Flipping the paradigm on organ transplants: a scientific multidisciplinary strategy combined with a patient-oriented approach study. Canadian Institutes of Health Research (CIHR). New Frontiers in Research Funds. 250 000 $. (2019-2021)
  • Grant. (Completed). Co-applicant. Montreal Immunology Meetings, Annual Meeting 2019. Canadian Institutes of Health Research (CIHR). Planning and dissemination grant. 10 000 $. (2019-2020)
  • Grant. (Completed). Co-applicant. Chronic Inflammation, Immunity and Cancer 2019. Canadian Institutes of Health Research (CIHR). Planning and dissemination grant. 15 000 $. (2019-2020)
  • Grant. (Completed). Principal Applicant. FRQS Chercheurs Boursiers, Junior 1. Fonds de recherche du Québec - Santé (FRQS). Chercheur Boursier, Junior 1. 246 321 $. (2016-2020)
  • Grant. (Completed). Co-investigator. Effects of catecholamine therapy on the immune system: unsuspected consequences of routine medical interventions and opportunities for individualized care - the OVATION study.. Merck Sharp & Dohme Research Laboratory. Universite de Sherbrooke. 67 000 $. (2017-2019)
  • Grant. (Completed). Principal Investigator. FRQS Chercheurs Boursiers Junior 1, Fonds d'Etablissement. Fonds de recherche du Québec - Santé (FRQS). Fonds d'Etablissement. 60 000 $. (2016-2019)
  • Grant. (Completed). Co-investigator. Epi-STORM, translational and multicentre study on the epigenetic regulation of the cytokine storm in organ donors on organ transplantation success.. CRCHUS. Projet Structurant. 75 000 $. (2018-2019)
  • Grant. (Completed). Principal Investigator. Oncolytic vesicular stomatitis virus for the treatment of non-muscle invasive bladder cancer in humanized mice. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Projet Structurant. 75 000 $. (2017-2019)
  • Grant. (Completed). Principal Investigator. Preventing postoperative cancer metastasis through regulation of NKG2D/NKG2DL axis in natural killer cells. CRCHUS. PAFI Institutional grant. 25 000 $. (2018-2019)
  • Grant. (Completed). Principal Investigator. Harnessing CRISPR/Cas9 technology for fundamental and translational cancer studies.. Universite de Sherbrooke, CRIODUS (Centre of Excellence). Technology development grant. 18 000 $. (2018-2019)
  • Grant. (Completed). Co-investigator. Generation of an orthotopic murine model to study the role of genetic and microenvironmental factors in carcinogenesis of pancreatic cancer.. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Projet Structurant. 75 000 $. (2016-2018)
  • Grant. (Completed). Co-investigator. Phase Ib trial of perioperative sildenafil and influenza vaccination in cancer patients undergoing laparotomy for surgical resection of a primary abdominal malignancy. CureAccelerator. Project Grant. 100 000 $. (2016-2018)
  • Grant. (Completed). Co-investigator. The Sherbrooke personalized colorectal cancer avatar models initiative (COLOR project): a feasibility study of treatment guided by the combination of a living organoids biobank and personalized avatars in patients with advanced. Merck Sharp & Dohme Research Laboratory. Universite de Sherbrooke. 250 000 $. (2016-2018)
  • Grant. (Completed). Principal Investigator. Preventing metastatic disease by boosting postoperative natural killer cell activity. Cancer Research Society (The). Scholarship for the Next Generation of Scientists. 160 000 $. (2015-2018)
  • Grant. (Completed). Principal Investigator. Adjuvant immunogenic cancer vaccine to treat metastatic solid tumors.. Merck Sharp & Dohme Research Laboratory. Universite de Sherbrooke. 67 000 $. (2017-2018)
  • Grant. (Completed). Co-investigator. Autotiss one semi-automatic tissue microarrayer. Centre de recherche du CHUS. Perc Internal Grant. 20 000 $. (2017-2018)
  • Grant. (Completed). Principal Investigator. Preventing postoperative cancer metastasis through regulation of immune cell metabolism. Canada Foundation for Innovation (CFI). John R. Evans Leaders Fund. 749 761 $. (2017-2018)
  • Grant. (Completed). Co-applicant. Combining oncolytic viruses with surgery and immune modulation to prevent postoperative cancer recurrence and metastases.. Canadian Cancer Society Research Institute (CCSRI). Innovation to Impact Grant. 450 000 $. (2015-2018)
  • Grant. (Completed). Co-investigator. Optimizing antibody-drug conjugate therapy by enhancing cellular accumulation – formulation development. Merck Sharp & Dohme Research Laboratory. Universite de Sherbrooke. 50 000 $. (2016-2017)
  • Grant. (Completed). Co-applicant. A personalized oncolytic vaccine: using oncolytic viruses to exploit neo-antigens derived from the tumour mutanome. Canadian Institutes of Health Research (CIHR). Terry Fox New Investigator Award. 450 000 $. (2012-2015)
  • Fellowship. (Completed). Principal Investigator. CIHR Fellowship. Canadian Institutes of Health Research (CIHR). Fellowship. 110 000 $. (2013-2015)
  • Grant. (Completed). Co-investigator. Adjuvant melatonin in the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): A phase II substudy of a randomized placebo controlled clinical trial. Gateway for Cancer Research (The). Cancer Research. 230 576 $. (2012-2015)
  • Grant. (Completed). Co-investigator. Prophylactic vaccines to reduce cancer metastases: a pilot study to assess natural killer cell activation. Ottawa Hospital (The). Department of Surgery Research Award. 25 000 $. (2012-2013)
  • Fellowship. (Completed). Principal Investigator. FRQS Fellowship. Fonds de recherche du Québec - Santé (FRQS). Fellowship. 135 000 $. (2010-2013)

Publications

Articles de revue

  • Rangsitratkul C*, Lawson C*, Bernier-Godon F*, Niavarani SR*, Boudaud M*, Rouleau S*, Corbin-Gadu AO, Surendran A, Ekindi-Ndongo N, Koti M, Ilkow CS, Richard P, and Tai LH * Tai lab trainees. (2022). Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer. Molecular Therapy Oncolytics 24 507-521. (Published).
  • Seely D, Legacy M, Auer RC, Fazekas A, Delic E, Anstee C, Angka L, Kennedy MA, Tai LH, Zhang T, Maziak DE, Shamji FM, Sundaresan RS, Gilbert S, Villeneuve PJ, Ashrafi AS, Inculet R, Yasufuku K, Waddell TK, Finley C, Shargall Y, Plourde M, Fergusson DA, Ramsay T, Seely AJE. (2021). Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): A randomized placebo controlled clinical trial. EClinicalMedicine 33 100763. (Published).
  • Baxter K, Tanese de Souza C, Tai LH, Yaghini P, Daneshmand M, Bell JC, Lichty BD, Kennedy M, Auer R. (2020). An easily adopted murine model of distal pancreatectomy for investigating immunotherapy efficacy in resectable pancreatic adenocarcinoma. Journal of Surgical Research - -. (Revision Requested).
  • Paquette M, Phoenix S, Lawson C*, Guérin B, Lecomte R, Tai LH, Turcotte EE, and Leyton JV. * Tai lab trainee. (2020). A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts. EJNMMI Res 10 (1), 69. (Published).
  • Niavarani SR*, Lawson C*, Boudaud M*, Simard C* and Tai LH. * Tai lab trainees. (2020). Oncolytic vesicular stomatitis virus based cellular vaccine recruits and activates natural killer and CD8+ T cells to improve outcome for triple negative breast cancer. Journal for ImmunoTherapy of Cancer 8 (1), e000465. (Published).
  • Niavarani S*, Lawson C*, Bakos O*, Boudaud M*, Batenchuk C, Rouleau S* and Tai LH. * Tai lab trainees. (2019). Lipid accumulation in natural killer cells leads to postoperative metastatic disease. BMC Cancer 19 (1), 823. (Published).
  • Niavarani SR*, Lawson C*, Tai LH. * Tai lab trainees. (2019). Treatment of Metastatic Disease through Natural Killer Cell Modulation by Infected Cell Vaccines. Viruses 11 (5), pii: E434. (Published).
  • Bakos O*, Rouleau S*, Lawson C and Tai LH. * Tai lab trainees. (2018). Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. Journal of ImmunoTherapy of Cancer 6 (1), 86. (Published).
  • Tai LH, Alkayyal AA, Leslie AL, Sahi S, Bennett S, Tanese de Souza C, Baxter KE, Angka L, Xu R, Kennedy M and Auer RC. (2018). Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cells. OncoImmunology 7 (6), e1431082. (Published).
  • Tai LH, Ananth AA, Seth R, Alkayyal A, Zhang J, de Souza CT, Staibano P, Kennedy MA, Auer RC. (2018). Sepsis increases perioperative metastases in a murine model. BMC Cancer 18 (1), 277. (Published).
  • Alkayyal AA, Tai LH, Kennedy MA, de Souza CT, Zhang J, Lefebvre C, Sahi S, Ananth AA, Mahmoud AB, Makrigiannis AP, Cron GO, Macdonald B, Marginean EC, Stojdl DF, Bell JC, Auer RC. (2017). NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine. Cancer Immunology Research 5 (3), 211-221. (Published).
  • Ananth AA, Tai LH, Lansdell C, Alkayyal AA, Baxter KE, Angka L, Zhang J, Tanese de Souza C, Stephenson KB, Parato K, Bramson JL, Bell JC, Lichty BD, and Auer RC. (2016). Surgical stress abrogates pre-existing protective T cell mediated anti-tumor immunity leading to postoperative cancer recurrence. PLoS One 11 (7), e0159471. (Published).
  • Tai LH, Tanese de Souza C, Sahi S, Zhang J, Alkayyal AA, Ananth AA, Auer RA. (2014). A mouse tumor model of surgical stress to explore the mechanisms of postoperative immunosuppression and evaluate novel perioperative immunotherapies. Journal of Visualized Experiments 12 (85), -. (Published).
  • Tai LH, Auer R. (2014). Attacking postoperative metastases using oncolytic virus and viral vaccines. Frontiers in Oncology 4 (217), -. (Published).
  • Zhang J, Tai LH, Ilkow C, Alkayyal AA, Ananth AA, Tanese de Souza C, Wang J, Sahi S, Ly L, Lefevbre C, Falls TJ, Stephenson KB, Mahmoud AB, Makrigiannis AP, Lichty BD, Bell JC, Stojdl DF, Auer RC. (2013). Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. Molecular Therapy 22 (7), 1320-1332. (Published).
  • McFall E, Tu MM, Al-Khattabi N, Tai LH, St-Laurent AS, Tzankova V, Hall CW, Belanger S, Troke AD, Wight A, Mahmoud AB, Zein HS, Rahim MM, Carlyle JR, Makrigiannis AP. (2013). Optimized tetramer analysis reveals Ly49 promiscuity for MHC ligands. Journal of Immunology 191 (11), 5722-9. (Published).
  • Tai-LH, Zhang J, Scott KJ, Tanese de Souza C, Alkayyal AA, Abhirami AA, Sahi S, Adair RA, Bakur Mahmoud A, Sad S, Bell JC, Makrigiannis AP, Melcher AA, Auer RC. (2013). Perioperative influenza vaccination reduces post-operative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. Clinical Cancer Research 19 (18), 5104-15. (Published).
  • Tai LH , de Souza CT , Bélanger S , Ly L , Alkayyal AA , Zhang J , Rintoul JL , Ananth AA , Lam T , Breitbach CJ , Falls TJ , Kirn DH , Bell JC , Makrigiannis AP , Auer RA. (2013). Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Research 73 (1), 97-107. (Published).
  • Bélanger S , Tu MM , Rahim MM , Mahmoud AB , Patel R , Tai LH , Troke AD , Wilhelm BT , Landry JR , Zhu Q , Tung KS , Raulet DH , Makrigiannis AP. (2012). Impaired natural killer cell self-education and "missing-self" responses in Ly49-deficient mice. Blood 120 (3), 592-602. (Published).
  • Tai LH, Rahim MM, Troke AD, Bakur Mahmoud A, Abou Samara E, Roy J, Mottashed A, Alt N, Corbeil C, Goulet ML, Zein HS, Hamilton MJ, Krystal G, Kerr WG, Toyama-Noriko N, Makrigiannis AP. (2012). Ly49Q positively regulates type I interferon production by plasmacytoid dendritic cells in an immunoreceptor tyrosine-based inhibitory motif-dependent manner. Journal of Immunology 190 (8), 3994-4004. (Published).
  • Rintoul JL , Lemay CG , Tai LH , Stanford MM , Falls TJ , de Souza CT , Bridle BW , Daneshmand M , Ohashi PS , Wan Y , Lichty BD , Mercer AA , Auer RC , Atkins HL , Bell JC. (2012). ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic. Molecular therapy : the journal of the American Society of Gene Therapy 20 (6), 1148-57. (Published).
  • Tai LH, Zhang J, Auer RC. (2012). Preventing surgery-induced NK cell dysfunction and cancer metastases with influenza vaccination. Oncoimmunology 2 (11), -. (Published).
  • Seth R , Tai LH , Falls T , de Souza CT , Bell JC , Carrier M , Atkins H , Boushey R , Auer RA. (2012). Surgical Stress Promotes the Development of Cancer Metastases by a Coagulation-Dependent Mechanism Involving Natural Killer Cells in a Murine Model. Annals of surgery 258 (1), 158-68. (Published).
  • Patel R , Bélanger S , Tai LH , Troke AD , Makrigiannis AP. (2010). Effect of Ly49 haplotype variance on NK cell function and education. Journal of immunology (Baltimore, Md. : 1950) 185 (8), 4783-92. (Published).

Articles de conférence

  • Niavarani S*, Lawson C, Tai LH. (2017). Characterizing an immunogenic autologous tumor cell vaccine for triple negative breast cancer. Summit for Cancer Immunotherapy. (Published).
  • Niavarani S*, Lawson C, Tai LH. (2017). Characterizing an immunogenic autologous tumor cell vaccine for triple negative breast cancer. New Investigator Meeting for the Institute of Immunology and Infection – Canadian Institutes of Health Research. (Published).
  • Niavarani S*, Lawson C, Tai LH. (2017). Surgical trauma impairs NK cell function through the NKG2D-NKG2DL pathway. Canadian Society for Immunology Spring Meeting. (Published).
  • Niavarani S*, Lawson C, Tai LH. (2017). Targeting postoperative triple negative breastcancer metastasis with an oncolytic virus infected autologous whole tumor cellvaccine. Canadian Cancer Research Conference. (Accepted).
  • Tai LH, Alkayyal AA, Zhang J, Tanese Souza C, Bennett S, Sahi S, Auer RC. (2016). Postoperative accumulation of myeloid derived suppressor cells inhibits natural killer cellfunction. AACR Special Meeting - Cancer Immunology and Immunotherapy. (Published).
  • Tai L-H, Alkayyal AA, Leslie AL, Zhang J, Tanese Souza C, Bennett S, Sahi S, Auer RC. (2015). Phosphodiesterase-5 inhibition augments postoperative natural killer cell antitumor immunity by reducing myeloid-derived suppressor cell function. The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival 2015, CRI-CIMT-EATI-AACR. (Published).
  • Tai L-H, Alkayyal AA, Zhang J, Tanese Souza C, Bennett S, Sahi S, Auer RC. (2015). Postoperative accumulation of myeloid derived suppressor cells inhibits natural killer cell function. NK2015, 15th Meeting of the Society for Natural Immunity. (Published).
  • Tai L-H, Alkayyal AA, Zhang J, Tanese Souza C, Bennett S, Sahi S, Auer RC. (2014). Postoperative accumulation of myeloid derived suppressor cells inhibits natural killer cell function. Ottawa Hospital Research Institute Research Day 2014. (Published).
  • Tai, LH, Zhang J, Alkayyal A, Ananth A, Tanese de Souza C, Sahi S, Auer RC. (2013). Targeting MDSC in the perioperative period with oncolytic virus to inhibit surgery-induced NK cell dysfunction. The 7th International Meeting on Replicating Oncolytic Virus Therapeutics 2013. (Published).
  • Tai L-H, Tanese Souza C, Seth R, Auer RC. (2013). Targeting postoperative natural killer cell dysfunction with novel preoperative immunotherapy. Ottawa Hospital Research Institute Research Day 2013. (Published).
  • Seth R, Tai LH, Lam T, Falls T, Souza C, Bell J, Atkins H, Boushey R, Auer RC. (2012). Perioperative Septic but Not Hemorrhagic Shock Promotes the Development of Cancer Metastases in a Murine Model. Ann Surg Oncol. (Published).
  • Seth R, Tai LH, Lam T, Falls T, Souza C, Bell J, Atkins H, Boushey R, Auer RC. (2012). Perioperative Septic but Not Hemorrhagic Shock Promotes the Development of Cancer Metastases in a Murine Model. Can J Surg. (Published).
  • Tai LH, Souza C, Seth R, Ly L, Auer R. (2012). Preventing perioperative cancer metastases formation by enhancing Natural Killer cell activity. Proceedings of the 103rd American Association for Cancer Research, Chicgao, Il. (Published).
  • Tai L-H, Tanese de Souza C, Belanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Abhirami AA, Lam T, Breitbach C, Falls TJ, Kirn DH, Bell JC, Makrigiannis AP, Auer RC. (2012). Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Collins' Day, Department of Surgery Research Day, University of Ottawa, Ottawa, Ontario. (Published).
  • Tai L-H, Tanese de Souza C, Belanger S, Ly L, Rintoul JL, Lam T, Bell JC, Makrigiannis AP, Auer RC. (2012). Preventing postoperative tumor metastases with novel oncolytic virus therapy. General Surgery Research Day, Division of General Surgery, University of Ottawa. (Published).
  • Tai L-H, Seth R, Tanese de Souza C, Auer RA. (2011). Effect of surgical stress on natural killer cell function. General Surgery Research Day 2011, Division of General Surgery, Ottawa, Ontario. (Published).
  • Tai L-H, Tanese de Souza C, Belanger S, Ly L, Rintoul JL, Lam T, Bell JC, Makrigiannis AP, Auer RC. (2011). Preventing postoperative metastatic disease with novel anti-cancer oncolytic virus therapy. Ottawa Hospital Research Institute Research Day 2011. (Published).
  • Seth R, Tai LH, Kus A, Falls T, Bell J, Carrier M, Atkins H, Boushey R, Auer R. (2011). Surgical stress promotes the development of cancer metastases by coagulation-dependent inhibition of natural killer cell mediated tumour cell clearance. Proceedings of 102nd American Association for Cancer Research, Orlando, Florida. (Published).
  • Tai L-H, Tanese Souza C, Seth R, Auer RA. (2010). Effect of surgical stress on natural killer cell function. Ottawa Hospital Research Day, Ottawa Hospital Research Institute, Ottawa, Ontario. (Published).

Propriétés intellectuelles

Patents

  • Recombinant VSV for the treatment of bladder cancer. 63/209,681. United States. (Pending).

Autres contributions

Présentations

  • (2022). Bladder cancer killing viruses. Canadian Cancer Society - Research Information Outreach Teams (RIOT) “Choosing Hope: Canadian Cancer Research” (CHCCR) 2022. Sherbrooke, Canada
  • (2022). Targeted virotherapy for bladder cancer. University of Western Ontario. London, Canada
  • (2021). Combining viroimmunotherapy with chemotherapy for pancreatic cancer. University of Windsor, Department of Biomedical Sciences. Canada
  • (2021). Intravesical immunotherapy with oncolytic rhabdovirus for the treatment of non-muscle invasive bladder cancer. Club de recherche clinique du Quebec 2021 annual meeting. Canada
  • (2021). Intravesical oncolytic rhabdovirus for the treatment of non-muscle invasive bladder cancer. Lady Davis Institute - Jewish General Hospital, Molecular Oncology Group seminar series. Montreal, Canada
  • (2020). An assistant professor’s guide to writing a scientific review paper. BioCanRx Webinar Series. Sherbrooke, Canada
  • (2020). Harnessing anti-viral immunity to treat cancer. Queen's University, invited speaker for Department of Pathology and Molecular Medicine seminar series. Kingston, Canada
  • (2019). Harnessing antiviral immunity for therapeutic gain. Chronic Inflammation, Immunity and Cancer Meeting. Eastman, Canada
  • (2018). Oncolytic virotherapy for tumor microenvironment modulation. University of Ottawa, Postdoctoral Association Research Day 2018. Ottawa, Canada
  • (2018). Targeting metastatic disease of triple negative breast cancer with an immunogenic cancer vaccine. CIACCO. St. Camille, Canada
  • (2018). Target metastatic triple negative breast cancer with an immunogenic cancer vaccine. Reseau de Recherche sur le Cancer (RRCancer, Quebec). Bromont, Canada
  • (2017). Targeting the postoperative window of opportunity to reduce metastatic disease. Invited speaker, Hopital Rosemont - Universite de Montreal. Montreal, Canada
  • (2016). Investigating the potential of sildenafil to treat metastatic disease after cancer surgery. 29th Annual Canadian Society for Immunology conference. Ottawa, Canada
  • (2016). Preventing metastases by targeting the perioperative period with innovative cancer immunotherapies. Journée scientifique de l'axe et du thème Cancer. Sherbrooke, Canada
  • (2015). Phosphodiester-5 inhibition reverses postoperative myeloid derived suppressor cell function. Ottawa Hospital Research Institute Research Day. Ottawa, Canada
  • (2015). Targeting natural killer an myeloid regulatory cells in the tumor microenvironment: preclinical research and translational opportunities. Division of Immunology, Department of Pediatrics, Universite de Sherbrooke, Special Guest Seminar. Sherbrooke, Canada
  • (2015). Targeting natural killer an myeloid regulatory cells in the tumor microenvironment: preclinical research and translational opportunities. Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Special Guest Seminar. Ottawa, Canada
  • (2012). Preventing post-operative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. OHRI Research Day. Ottawa, Canada
  • (2012). Preventing post-operative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Collins Day - Department of Surgery Research Day. Ottawa, Canada
  • (2011). Effect of surgery stress on natural killer cell function. Division of General Surgery Research Day, Faculty of Medicine, University of Ottawa. Ottawa, Canada
  • (2011). Novel anti-cancer oncolytic virus therapy to enhance perioperative natural killer cell activation. Post-doctoral Fellow Research Day, Faculty of Medicine, University of Ottawa. Ottawa, Canada
  • (2009). Positive regulation of plasmacytoid dendritic cell function via Ly49Q recognition of Class I MHC. 2nd European Congress in Immunology 2009, Berlin, Germany. Berlin, Germany